CSL Plasma, a division of global biotherapeutics pioneer CSL Behring, announced the Rika Plasma Donation System created by Terumo Blood and Cell Technologies, a medical technology company based in Lakewood, Colorado, has received regulatory approval.
The new plasmapheresis system is expected to provide technologies to support a safe, efficient, and better experience for plasma donors and an improved experience for CSL Plasma personnel, according to Terumo Blood and Cell Technologies.
Additional characteristics of the new Rika system, according to CSL Plasma, will allow for the collection of more plasma in less time, hence improving quality and safety and, in turn, better serving patients who rely on plasma-based therapies. These advantages include:
On average, Rika completes one plasma collection in 35 minutes or less: Compared to previous average CSL Plasma donation timings, this might mean a nearly 30% reduction in donor donation time.
It assures that no more than 200 milliliters of blood are ever removed from the donor's body. This is believed to make the donor more comfortable during the donation process and lessen the risk of red cell loss deferral.
It has a sophisticated user interface that helps CSL Plasma front-line personnel operate the equipment.
This milestone helps bring to life how we demonstrate innovation, collaboration, and patient-focus, part of the CSL Values that underpin our commitment to manufacturing and delivering life-saving and life-extending medicines around the world, We continue to evolve as a leading biotechnology company, investing in our core plasma business. Continued innovation that benefits our employees and plasma donors speak to how we are driven by our promise to save and improve lives around the world."
CSL Chief Operating Officer Paul McKenzie.
CSL Plasma will begin installing the new technology at locations in the Denver, Colorado, area in the following months.
There is a critical and ongoing need for human plasma to produce life-saving medicines for people with serious and rare diseases, CSL Plasma's decision to work with Terumo Blood and Cell Technologies is consistent with our business goals to improve the donor and employee experience through innovation and remain the plasma donation center of choice. We look forward to rolling out this new technology."
CSL Plasma General Manager Michelle Meyer.